December 15, 2023 7:48am
“Emphasizes the importance of accuracy, consistency, and a controlled pace in executing tasks. Contrary to popular belief, the fastest route to profit isn't always about rushing headlong into selling.” Market spectators caution that markets could be getting ahead of themselves; when the share pricing slippage starts, react with RMi’s intel!
Pre-open Indications: 1 Positive, 2 Negative and 2 Sell into Strength Indications
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
Never leave an investor uninformed!
Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.
One of my usual questions, are we facing a prisoner’s dilemma - a situation wherein algorithms acting with electronic trading interest do not achieve a continued optimal outcome for this sectors investor group.
The pre-open Dow futures are UP +0.27% or (+103 points), the S&P is UP +0.25 or (+12 points) as the Nasdaq is UP +0.34% or (+56 points)
U.S. stock futures are up and climbing on Friday,
European markets were higher,
Asia-Pacific markets climbed Friday.
Henry’omics:
We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …
Another fresh record high for the Dow on Thursday rising +158 points, or 0.43% at 37,248.35, the S&P 500 gained 0.26% to 4,719.55 while the Nasdaq rose 0.19% to 14,761.56.
As of Thursday, the Dow was higher on the week by 2.8%, the S&P 500 is up by 2.5%, while the Nasdaq rose 2.5% this week.
Economic Data Docket: Economic data: Empire Manufacturing, December (2.0 expected, 9.1 previously); Industrial production, month-over-month, November (+0.3% expected, -0.6% previously); S&P Global US Manufacturing PMI, December preliminary (49.3 expected, 49.4 previously); S&P Global US Services PMI, December preliminary (50.7 expected, 50.8 prior)
Thursday, RegMed Investors (RMi) Closing Bell: “Fly me to the moon, let me play among the stars. Playing among the stars means a portfolio feels dazzled before it falls out of love or sentiment” … https://www.regmedinvestors.com/articles/13247
Q4: December – 6 positive and 4 negative closes
- November – 11 positives, 1 holiday and 10 negative closes
- October – 1 sick day, 9 positive and 12 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context: looking for lost SHEAP …
I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Sell into Strength Indication:
Thursday’s closing price, some Wednesday, Tuesday, Monday, Friday, Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Alnylam Pharmaceuticals (ALNY) closed up +$5.96 after Wednesday’s +$4.64, Tuesday’s +$2.96 and Monday’s +$0.88, last Friday’s -$7.22 followed by the previous Thursday’s +$2.24, Wednesday’s +$4.65, Tuesday’s -$2.50 and Monday’s +$1.36 with a positive +$1.90 or +1.02% l pre-open indication
Intellia Therapeutics (NTLA) closed up +$1.47 after Wednesday’s +$2.24, Tuesday’s -$0.20, Monday’s -$0.67 and last Friday’s -$0.76, following the previous Thursday’s -$0.08, Wednesday’s -$0.04 with a positive +$0.81 or +2.54% pre-open indication
Negative Indications:
Thursday’s closing price, some Wednesday, Tuesday, Monday, Friday, Thursday, Wednesday, Tuesday, Monday and last Friday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Beam Therapeutics (BEAM) closed up +$1.51 after Wednesday’s +$2.24, Tuesday’s -$0.61, Monday’s +$0.25, and last Friday -$2.35 followed by the previous Thursday’s -$0.08, Wednesday’s +$0.42, Tuesday’s -$1.31 and Monday’s -$0.01 with a negative -$0.32 or -1.07% pre-open indication
CRISPR Therapeutics (CRSP) closed up +$1.51 after Wednesday’s +$3.31, Tuesday’s -$2.16, Monday’s -$4.26, and last Friday’s -$5.67, followed by the previous Thursday’s -$0.93, Wednesday’s +$0.54 and Tuesday’s -$0.91 with a positive +$0.256 or -0.89% pre-open indication.
Positive Indications:
Thursday’s closing price, some Wednesday, Tuesday, Monday, Friday, Thursday, Wednesday, Tuesday, Monday closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Sage Therapeutics (SAGE) closed -$0.14 after Wednesday’s +$1.55 and Tuesday’s -$0.22 with a positive +$0.29 or +1.37% aftermarket indication.
The BOTTOM LINE: Repeat, again, and again – I say … what changes … as I reiterate … “I remain a skeptic, as electronic trading remains the impetus to, I believe a cell and gene therapy sector’s artificial high” … as proven today yet again!
- If Jerome Powell Fed Chair sees an “uncertain" path forward” – I agree as the impetus to drive the ascension of the cell and gene therapy sector … came out of now where after many CRISP
- I say the emperor’s new clothes i.e., driven equities get stripped after being cut to pieces suddenly their seeing sunlight … but, what’s next?
- I warned that sector portfolios containing cell and gene therapy sector equities should consider getting defensive” … “Investors NEED to start formulating their portfolio outlook into next year.”
Definitely …Not changing my “tune” … I remain a skeptic, thus maintaining; investors should consider getting defensive…
- If dead wood or too struggling share pricings are in the portfolio; especially those desperately needing a financing, lacking a partner, restructuring and just wallowing in the market …
- I am STILL waiting for catalysts to justify recent upside appreciation as some news sinks the share pricing other than algorithmic electronic trading!
While optimism for December remains high, some analysts worry the run-up has been too big, too fast. <The Street>
- Again, it might be prudent to harvest and cash in some chips following the past month’s dramatic rally.
- It’s up to you to decide!
It's time to think ahead to December. It's usually an important month for the Nasdaq.
- Don’t FORGET portfolio tax selling and a bit of rebalancing
- And then comes January and with worries that the U.S. economy will be slowing down, the potential for continued Middle East violence and, of course, the real prospect of bitterly contested elections across all of the United States. <The Street>
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
